Catalyst Pharmaceutical Partners Launches New Website

Catalyst Pharmaceutical Partners Launches New Website

CORAL GABLES, Fla., Feb. 21, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical
Partners, Inc. (Nasdaq:CPRX), a specialty pharmaceutical company focused on
the development and commercialization of novel prescription drugs targeting
rare (orphan) neurological diseases and disorders, is pleased to announce the
launch of its newly designed website. The site can be accessed at

"As we continue to make progress and further our plans for the transformation
of Catalyst to a company developing novel prescription drugs to treat rare
neurological diseases, we felt that it was important to upgrade and revamp our
website," said Patrick J. McEnany, Chief Executive Officer of Catalyst.

About the Website

The site provides an information platform for patients, physicians and
investors in an easy to navigate format.

The aim of the site is to allow visitors to gain a comprehensive understanding
of the Company's drug candidates. Patients and other interested parties can
learn about Catalyst's drug candidates, related clinical trials and the
science behind them. Website visitors will have an ability to follow the
progress of the drug candidates and Company's development in the News and
Events sections. Current and potential investors will have the ability to
download the latest information on the Company in the Investors section.

In keeping with Catalyst's mission to provide treatment for rare neurological
diseases through collaboration with patients, physicians, scientists and other
constituencies, the new website also offers multiple ways of contacting the
Company.All the inputs will be carefully reviewed and will serve as a basis
for further development of the website.The ultimate goal is to eventually
expand the website into a forum for patients, physicians and other
stakeholders to share information, ideas and recommendations.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc., is a specialty pharmaceutical company
focused on the development and commercialization of prescription drugs
targeting rare (orphan) neurological diseases and disorders, including
Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's
syndrome. Catalyst's lead candidate, Firdapse^TM for the treatment of LEMS, is
currently undergoing testing in a global, multi-center, pivotal phase III
trial. Catalyst is also developing a potentially safer and more potent
vigabatrin analog (designated CPP-115 by Catalyst) to treat infantile spasms,
and epilepsy, as well as other neurological conditions associated with reduced
GABAergic signaling, like post-traumatic stress disorder, Tourette's disorder,
and movement disorders associated with the treatment of Parkinson's Disease.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking
statements involve known and unknown risks and uncertainties, which may cause
the Company's actual results in future periods to differ materially from
forecasted results. A number of factors, including whether any of the
Company's product candidates will ever be approved for commercialization and
those factors described in the Company's filings with the U.S. Securities and
Exchange Commission (SEC), could adversely affect the Company. Copies of the
Company's filings with the SEC are available from the SEC, may be found on the
Company's website or may be obtained upon request from the Company. The
Company does not undertake any obligation to update the information contained
herein, which speaks only as of this date.

CONTACT: Patrick J. McEnany
         Catalyst Pharmaceutical Partners
         Chief Executive Officer
         (305) 529-2522
         Melody Carey
         Rx Communications Group
         (917) 322-2571
Press spacebar to pause and continue. Press esc to stop.